Figure 1:




Trial 1
Trial 2
A
WASO
B
WASO
C
LPS
D
LPS
E
sTST
F
sTST
G
IDSIQ sleepiness domain
H
IDSIQ sleepiness domain
LSM change from baseline, min (95% CI)
p<0.001
p=0.0028
p=0.0015
p=0.0334
p=0.0013
No. of patients Baseline Month 1 Month 3
Placebo 310 299 283
Daridorexant 25 mg 310 298 289
Daridorexant 50 mg 310 305 287
No. of patients Baseline Month 1 Month 3
Placebo 308 300 283
Daridorexant 10 mg 307 302 278
Daridorexant 25 mg 309 295 281
No. of patients Baseline Month 1 Month 3
Placebo 310 302 289
Daridorexant 25 mg 310 303 292
Daridorexant 50 mg 310 304 289
No. of patients Baseline Month 1 Month 3
Placebo 308 300 287
Daridorexant 10 mg 307 304 289
Daridorexant 25 mg 309 297 285
No. of patients Baseline Month 1 Month 3
Placebo 310 301 288
Daridorexant 25 mg 310 301 290
Daridorexant 50 mg 310 304 291
No. of patients Baseline Month 1 Month 3
Placebo 308 297 289
Daridorexant 10 mg 307 304 286
Daridorexant 25 mg 309 297 283
Placebo
Daridorexant 10 mg
Daridorexant 25 mg
Daridorexant 50 mg

Figure 2 :


Trial 1
Trial 2
A
IDSIQ alert/ cognition domain
LSM change from baseline, score (95% CI)
No. of patients Baseline Month 1 Month 3
Placebo 310 301 288
Daridorexant 25 mg 310 301 290
Daridorexant 50 mg 310 304 291
B
IDSIQ alert/ cognition domain
LSM change from baseline, score (95% CI)
No. of patients Baseline Month 1 Month 3
Placebo 308 297 289
Daridorexant 10 mg 307 304 286
Daridorexant 25 mg 309 297 283
C
IDSIQ mood domain
LSM change from baseline, score (95% CI)
No. of patients Baseline Month 1 Month 3
Placebo 310 301 288
Daridorexant 25 mg 310 301 290
Daridorexant 50 mg 310 304 291
D
IDSIQ mood domain
LSM change from baseline, score (95% CI)
No. of patients Baseline Month 1 Month 3
Placebo 308 297 289
Daridorexant 10 mg 307 304 286
Daridorexant 25 mg 309 297 283
E
IDSIQ total score
LSM change from baseline, score (95% CI)
No. of patients Baseline Month 1 Month 3
Placebo 310 301 288
Daridorexant 25 mg 310 301 290
Daridorexant 50 mg 310 304 291
F
IDSIQ total score
LSM change from baseline, score (95% CI)
No. of patients Baseline Month 1 Month 3
Placebo 308 297 289
Daridorexant 10 mg 307 304 286
Daridorexant 25 mg 309 297 283
Placebo
Daridorexant 10 mg
Daridorexant 25 mg
Daridorexant 50 mg